The blood test helps in measuring filamin A, a crucial biological prostate cancer driver. Credit: OsloMetX from Pixabay.

BPGbio has entered a collaborative agreement with Grupo Terralpe for the commercialisation of its prostate cancer diagnostic test, pstateDx, in Mexico.

The pstateDx test is claimed to be the first diagnostic product discovered leveraging BPGbio’s artificial intelligence-driven platform, Interrogative Biology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Grupo Terralpe CEO Javier Prieto said: “BPGbio’s pstateDx test will enhance our healthcare offering and we are eager to bring the benefits of this novel prostate cancer diagnostic test to Mexico.”

The non-prostate-specific antigen-based molecular diagnostic blood test helps measure filamin A, a crucial biological prostate cancer driver.

Clinicians can use the risk score offered by the test for differentiating between benign prostatic hyperplasia (BPH) and aggressive prostate cancer at the initial screening time.

It was estimated that roughly 2.3 million men in Mexico had been diagnosed with BPH, according to a study published in 2019.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BPGbio CEO and president Niven Narain said: “Through our strategic partnership, Grupo Terralpe will bring the pstateDx test, BPGbio’s novel prostate cancer test to Mexico in an effort to improve clinical decision support for patients with elevated PSA levels who may have prostate cancer.

“We believe that this test will reduce the need for invasive biopsies and their associated risks and costs in patients with BPH.”

BPGbio is seeking business prospects in various countries to expand the reach of its diagnostic technology.

The pstateDx test is currently unavailable for commercial use within the US.